Good morning. I grew up in Florida and did not know about the rest of the country's jokes at our expense until I left for college, but sure, I'll join in: Florida home sees freak toilet explosion during thunderstorm.
Today's word count is not explosive: 678 words, or 2.5 minutes.
Illustration: Aïda Amer/Axios
Health care companies are trying to fend off tech giants with one hand while striking up partnerships with them with the other.
Between the lines: Whether health care companies love or hate big tech's encroachment into their territory is dependent on whether they stand to make or lose money should the tech companies succeed.
Driving the news: The feuds between Amazon's PillPack and established industry players like CVS, Walgreens and UnitedHealth have illustrated these major health companies' resistance to a new competitor.
The other side: Also this week, CNBC reported that Eli Lilly is working with Apple to see whether health features on the iPhone and Apple Watch can be used to spot early signs of dementia.
The bottom line: Technology itself can offer real value to patients and therefore to health care companies. But the tech industry’s desire to claim a piece of our ever-growing health care spending is an existential threat to the incumbent players.
Gun violence research is underfunded compared to other leading causes of death in the U.S., my colleague Marisa Fernandez reports.
Why it matters: A dearth of research allows misinformation to spread, including from Trump and other Republicans this week when they correlated violent video games with mass shootings and conflated mental illness with gun violence.
Competition doesn’t bring down drug prices until there’s a whole lot of it, Axios’ Sam Baker writes.
How it works: Kaiser Health News and NPR illustrate this point well, using the example of antivenom to treat snakebites.
Both drugs are biologics, so patent litigation is also keeping prices high.
Allscripts Healthcare Solutions said yesterday that it's reached a tentative settlement with the Department of Justice to resolve an investigation into Practice Fusion, which it acquired last year, Modern Healthcare reports.
There hasn't been much innovation in women's birth control since the pill came to market nearly 60 years ago — because drug companies don't stand to make much from it, Bloomberg reports.
By the numbers: Only 2% of drug companies' annual revenue from contraceptives goes back into research and development, according to the Gates Foundation.